{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:31:55Z","timestamp":1791027115361,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003181","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T00:00:00Z","timestamp":1192579200000}}],"reference-count":111,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003181.pub2","type":"journal-article","created":{"date-parts":[[2007,10,10]],"date-time":"2007-10-10T12:19:30Z","timestamp":1192018770000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Bile acids for viral hepatitis"],"prefix":"10.1002","volume":"2009","author":[{"given":"Wendong","family":"Chen","sequence":"first","affiliation":[{"name":"Toronto Health Economics and Technology Assessment Collaborative (THETA), University of Toronto; Departments of Health Policy Management and Evaluation, and Pharmacy; Room 679, 6th floor, Leslie L. Dan Pharmacy Building 144 College Street Toronto Ontario Canada M5S 3M2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing University of Chinese Medicine; Centre for Evidence-Based Chinese Medicine; 11 Bei San Huan Dong Lu, Chaoyang District Beijing China 100029"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital; Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Denmark DK-2100"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,17]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00004836-199803000-00009","article-title":"Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid","volume":"26","author":"Abdelmalek","year":"1998","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0002|cit2","unstructured":"Angelico M Gandin C Pescarmona E Rapicetta M Del Vecchio C Goffredo F Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial Italian Journal of Gastroenterology 1993 446"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0003|cit3","first-page":"263","article-title":"Recombinant interferon alpha and ursodeoxycholic acid versus interferon alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up","volume":"90","author":"Angelico","year":"1995","journal-title":"The American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003181.pub2-BIB0004|cit4","first-page":"427","article-title":"Effect of tauroursodeoxycholic acid on ALT, GGT and viral load in patients with hepatitis C virus-related chronic hepatitis with reference to the genotype","volume":"31","author":"Belloni","year":"1999","journal-title":"The Italian Journal of Gastroenterology and Hepatology"},{"issue":"4 Pt.2","key":"10.1002\/14651858.CD003181.pub2-BIB0005|cit5","first-page":"403A","article-title":"Interferon alfa and ursodeoxycholic acid combination versus interferon alone in the treatment of chronic hepatitis C: Results of a randomized trial [AASLD abstract]","volume":"24","author":"Bonnand","year":"1996","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0006|cit6","unstructured":"Boucher E Andre P Jouanolle H Moirand R Guyader D Ruffault A Treatment of chronic viral C hepatitis by interferon plus ursodeoxycholic acid: results from a controlled randomized trial in 80 patients Hepatology 1994 169A"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0007|cit7","first-page":"322","article-title":"Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients","volume":"21","author":"Boucher","year":"1995","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD003181.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/01.TP.0000055831.63841.B6","article-title":"Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study","volume":"75","author":"Cadranel","year":"2003","journal-title":"Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003181.pub2-BIB0009|cit9","first-page":"S102","article-title":"Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis","volume":"21","author":"Clerici","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"23","key":"10.1002\/14651858.CD003181.pub2-BIB0010|cit10","first-page":"1624","article-title":"Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study","volume":"45","author":"Crosignani","year":"1998","journal-title":"Hepato-Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003181.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00042737-200012050-00006","article-title":"Efficacy of ursodeoxycholic acid in association with interferon alpha for chronic hepatitis C in interferon alpha non-responder patients","volume":"12","author":"Fabbri","year":"2000","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0012|cit12","unstructured":"Fabbri C Mazzella G Marchetto A Pezzoli E Accogli P Fusaroli F Efficacy of ursodeoxycholic acid administration as adjuvant therapy together with alfa-interferon for chronic hepatitis C Journal of Hepatology 1997 S179"},{"issue":"3","key":"10.1002\/14651858.CD003181.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00004836-199904000-00013","article-title":"Effect of ursodeoxycholic acid in acute viral hepatitis","volume":"28","author":"Galsk\u00fd","year":"1999","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD003181.pub2-BIB0014|cit14","first-page":"338","article-title":"Combined interferon and ursodeoxycholic acid therapy in 48 chronic hepatitis C patients","volume":"5","author":"Ge","year":"1997","journal-title":"Journal of New Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1386-6346(02)00007-4","article-title":"A controlled randomised trial of t-UDCA as adjuvant to interferon for treatment of chronic hepatitis C: an interferon sparing effect of t-UDCA","volume":"23","author":"Gracielle","year":"2002","journal-title":"Hepatology Research"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0016|cit16","first-page":"32","article-title":"Ursodeoxycholic acid therapy in chronic hepatitis C patients","volume":"5","author":"Huang","year":"1997","journal-title":"Acta Academic Medicine CPAPF (Chinese People Armed Police Force)"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0017|cit17","first-page":"363A","article-title":"Efficacy of combination therapy of interferon with ursodeoxycholic acid in chronic hepatitis C: sustained clearance of viremia after interferon discontinuation","volume":"20","author":"Kawata","year":"1994","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003181.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/BF01213297","article-title":"Efficacy of combination therapy of interferon alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial","volume":"32","author":"Kiso","year":"1997","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0019|cit19","first-page":"15","article-title":"Ursodeoxycholic acid, interferon-alfa, versus interferon-alfa + ursodeoxycholic acid in chronic C hepatitis","volume":"9","author":"Leri","year":"1994","journal-title":"Mediterranean Journal of Infectious and Parasitic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD003181.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0011-393X(05)80802-1","article-title":"Effect of therapy with combined interferon and tauroursodeoxycholic acid in chronic hepatitis C: biochemical and virologic evaluation","volume":"55","author":"Picciotto","year":"1994","journal-title":"Current Therapeutic Research"},{"issue":"6","key":"10.1002\/14651858.CD003181.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1080\/003655200750023624","article-title":"Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon","volume":"35","author":"Poupon","year":"2000","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0022|cit22","first-page":"151","article-title":"Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease","volume":"7","author":"Puoti","year":"1995","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Puoti C Pannullo A Annovazzi G Filippi T Magrini A Ursodeoxycholic acid and chronic hepatitis C infection The Lancet 1993 1413 4","DOI":"10.1016\/0140-6736(93)90981-L"},{"issue":"1","key":"10.1002\/14651858.CD003181.pub2-BIB0024|cit24","first-page":"48","article-title":"The effeicacy of ursodeoxycholic acid on chronic hepatitis","volume":"14","author":"Qing","year":"1999","journal-title":"Journal of North Sichuan Medical College"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0025|cit25","first-page":"168","article-title":"The ursodeoxycholic acid for the treatment of HCV infections","volume":"3","author":"Scotto","year":"1997","journal-title":"Infezioni in Medicine"},{"issue":"7","key":"10.1002\/14651858.CD003181.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1023\/A:1018854424403","article-title":"Long-term efficacy of interferon alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis","volume":"42","author":"Senturk","year":"1997","journal-title":"Digestive Diseases and Sciences"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/0270-9139(94)90683-1","article-title":"A multi-center randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C","volume":"19","author":"Takano","year":"1994","journal-title":"Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD003181.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1440-1746.1996.tb01844.x","article-title":"Efficacy of ursodeoxycholic acid in combination with interferon alpha in treating chronic hepatitis C: results of a long-term follow-up trial","volume":"11","author":"Tanaka","year":"1996","journal-title":"Journal of Gastroenterology & Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD003181.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/00042737-199910000-00002","article-title":"Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients","volume":"11","author":"Tsubota","year":"1999","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"4 Pt.2","key":"10.1002\/14651858.CD003181.pub2-BIB0030|cit30","first-page":"594A","article-title":"Predictive factors of non-response to recombinant interferon alfa 2b in patients with chronic hepatitis C (AASLD abstract)","volume":"24","author":"Viola","year":"1996","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0031|cit31","first-page":"290A","article-title":"A randomized controlled trial of 12-month treatment with interferon alfa 2b and ursodeoxycholic acid for chronic hepatitis C","volume":"28","author":"Viola","year":"1998","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003181.pub2-BIB0032|cit32","first-page":"148","article-title":"Efficacy of ursodeoxycholic acid therapy on chronic hepatitis","volume":"11","author":"Zhou","year":"1995","journal-title":"Journal of Clinical Hepato-Biliary Diseases"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0033|cit33","first-page":"237","article-title":"Efficacy of ursodeoxycholic acid therapy on chronic hepatitis C","volume":"14","author":"Zhu","year":"1994","journal-title":"Bulletin of Nantong Medical College"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003181.pub2-BIB0034|cit34","first-page":"120A","article-title":"Interferon-alpha and tauroursodeoxycholic acid in chronic hepatitis C: a novel therapeutic combination (AASLD abstract)","volume":"22","author":"Angelico","year":"1995","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003181.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0168-8278(94)80001-4","article-title":"The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis","volume":"20","author":"Attilli","year":"1994","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003181.pub2-BIB0036|cit36","first-page":"635","article-title":"Long-term treatment with ursodeoxycholic acid in patients with chronic active hepatitis","volume":"50","author":"Buzzelli","year":"1991","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0037|cit37","first-page":"537","article-title":"Ursodeoxycholic acid-hemisuccinate in the treatment of chronic active hepatitis. A controlled clinical study","volume":"83","author":"Buzzelli","year":"1992","journal-title":"Minerva medica"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hep.1840130222","article-title":"Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study","volume":"13","author":"Crosignani","year":"1991","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1386-6346(98)00070-9","article-title":"Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a multicentre dose-response study","volume":"13","author":"Crosignani","year":"1998","journal-title":"Hepatology Research"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/030006058201000416","article-title":"Safe use of ursodeoxycholic acid in the treatment of dyspeptic symptoms in patients with chronic active hepatitis: A double-blind controlled trial","volume":"10","author":"Vecchio Blanco","year":"1982","journal-title":"The Journal of International Medical Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003181.pub2-BIB0041|cit41","first-page":"S32","article-title":"UDCA improves serum liver enzymes but not liver histology in chronic hepatitis","volume":"11","author":"Italian Multicenter Group for Ursodeoxycholic Therapy in Chronic Hepatitis","year":"1990","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004836-199703000-00021","article-title":"Ursodeoxycholic acid in the management of prolonged cholestasis of acute hepatitis B","volume":"24","author":"Kadayifci","year":"1997","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1440-1746.1995.tb01596.x","article-title":"Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C","volume":"10","author":"Lu","year":"1995","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD003181.pub2-BIB0044|cit44","first-page":"359","article-title":"Effect of therapy with bis-hemisuccinate of ursodeoxycholic acid bisodic salt in patients with chronic liver diseases","volume":"83","author":"Pinto","year":"1992","journal-title":"Minerva Medica"},{"issue":"12","key":"10.1002\/14651858.CD003181.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01536665","article-title":"Effect of different doses of ursodeoxycholic acid in chronic liver disease","volume":"34","author":"Podda","year":"1989","journal-title":"Digestive Diseases and Sciences"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0016-5085(90)90032-V","article-title":"Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis","volume":"98","author":"Podda","year":"1990","journal-title":"Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD003181.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"120A","DOI":"10.1016\/0270-9139(95)94204-1","article-title":"Tauroursodeoxycholic acid for the treatment of chronic hepatitis: A dose-response study (AASLD abstract)","volume":"22","author":"Podda","year":"1995","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD003181.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0011-393X(05)80659-9","article-title":"Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis","volume":"53","author":"Portincasa","year":"1993","journal-title":"Current Therapeutic Research"},{"issue":"5","key":"10.1002\/14651858.CD003181.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00315225","article-title":"Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis","volume":"40","author":"Rolandi","year":"1991","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0050|cit50","first-page":"106","article-title":"The effect of UDCA on 42 chronic hepatitis patients with persisting high level of gamma GT","volume":"8","author":"Song","year":"1998","journal-title":"Chinese Journal of Intergretive Traditional and Western Medicine on Liver Diseases"},{"issue":"1","key":"10.1002\/14651858.CD003181.pub2-BIB0051|cit51","first-page":"44","article-title":"Combination of UDCA, Bing Du Zuo, and Ju Jibao for the treatment on 53 chronic hepatitis C patients (Chinese)","volume":"20","author":"Zhu","year":"1997","journal-title":"Bulletin of Jiamusi Medical College"},{"issue":"6","key":"10.1002\/14651858.CD003181.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/0958-1669(95)80113-8","article-title":"Interferon-beta treatment of human disease","volume":"6","author":"Alam","year":"1995","journal-title":"Current Opinion in Biotechnology"},{"issue":"1","key":"10.1002\/14651858.CD003181.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0022-2275(20)38175-X","article-title":"The hydrophobic-hydrophilic balance of bile salt. Inverse correlation between reversephase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities","volume":"23","author":"Armstrong","year":"1982","journal-title":"Journal of Lipid Research"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.1840100404","article-title":"Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis","volume":"10","author":"Batta","year":"1989","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0055|cit55","first-page":"322","article-title":"Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral hepatitis: results from a controlled randomized trial in 80 patients","volume":"21","author":"Boucher","year":"1995","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0950-3528(96)90010-X","article-title":"Hepatitis B and C viruses and primary liver cancer","volume":"10","author":"Brechot","year":"1996","journal-title":"Baillieres Clinical Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005445","article-title":"Ribavirin plus interferon versus interferon for chronic hepatitis C","author":"Brok","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003181.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.1840110104","article-title":"Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid","volume":"11","author":"Calmus","year":"1990","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD003181.pub2-BIB0059|cit59","article-title":"Bile acids for viral hepatitis (Protocol for a Cochrane Review)","author":"Chen","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0060|cit60","article-title":"Bile acids for primary sclerosing cholangitis (Protocol for a Cochrane Review)","author":"Chen","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0061|cit61","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003626","article-title":"Bile acids for primary sclerosing cholangitis","author":"Chen","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD003181.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/gut.30.8.1110","article-title":"Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment","volume":"30","author":"Chretien","year":"1989","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD003181.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/sim.4780060325","article-title":"Methods for combining randomized clinical trials: strengths and limitations","volume":"6","author":"DeMets","year":"1987","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003181.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"7109","key":"10.1002\/14651858.CD003181.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD003181.pub2-BIB0066|cit66","first-page":"2596","article-title":"Chronic hepatitis C: how to recognize, when to treat","volume":"37","author":"Fallon","year":"1997","journal-title":"Consultant"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0067|cit67","first-page":"4(i","article-title":"Management of hepatitis C","volume":"Suppl","author":"Farrell","year":"1999","journal-title":"Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003181.pub2-BIB0068|cit68","first-page":"77","article-title":"Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B","volume":"21","author":"Fattovich","year":"1995","journal-title":"Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003181.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0070|cit70","first-page":"223","article-title":"Metabolism of bile acids","volume-title":"Oxford Textbook of Clinical Hepatology","volume":"1","author":"Fuchs","year":"1999"},{"issue":"5","key":"10.1002\/14651858.CD003181.pub2-BIB0071|cit71","first-page":"421","article-title":"Tauro-ursodeoxycholic acids vs ursodeoxycholic acid in the dissolution of biliary calculi. Result of a single blind study","volume":"143","author":"Gallo","year":"1993","journal-title":"La Clinica Terapeutica"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0072|cit72","first-page":"322","article-title":"Alcoholic hepatitis: no glucocorticosteroids?","volume-title":"Steatohepatitis (NASH and ASH)-Falk Symposium 121","author":"Gluud","year":"2001"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Gluud","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"9184","key":"10.1002\/14651858.CD003181.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1053\/jhep.2002.32931","article-title":"Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways","volume":"35","author":"Guicciardi","year":"2002","journal-title":"Hepatology"},{"issue":"24","key":"10.1002\/14651858.CD003181.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1002\/1097-0258(20001230)19:24<3325::AID-SIM827>3.0.CO;2-D","article-title":"Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies","volume":"19","author":"Hahn","year":"2000","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0078|cit78","article-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]","volume-title":"The Cochrane Library, Issue 3","author":"Higgins","year":"2005"},{"issue":"5","key":"10.1002\/14651858.CD003181.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199701303360507","article-title":"The treatment of chronic viral hepatitis","volume":"336","author":"Hoffnagle","year":"1997","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0080|cit80","volume-title":"Code of Federal Regulations & International Conference on Harmonization Guidelines","author":"International Conference on Harmonisation Expert Working Group","year":"1997"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/toxsci\/65.2.166","article-title":"Mechanisms of hepatotoxicity","volume":"65","author":"Jaeschke","year":"2002","journal-title":"Toxicological Sciences"},{"issue":"11","key":"10.1002\/14651858.CD003181.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003181.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2036.1997.124295000.x","article-title":"Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study","volume":"11","author":"Larghi","year":"1997","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0085|cit85","first-page":"2 (i-viii)","article-title":"Management of chronic hepatitis B","volume":"Supplement","author":"Liaw","year":"1999","journal-title":"Gastroenterology and Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003181.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1142\/S0192415X0200017X","article-title":"Misuse of randomization: a review of Chinese randomized trials of herbal medicines for chronic hepatitis B","volume":"30","author":"Liu","year":"2002","journal-title":"American Journal of Chinese Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003181.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/jhep.2001.29401","article-title":"Chronic hepatitis B","volume":"34","author":"Lok","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003181.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0300-5089(21)00714-8","article-title":"Drug-related acute and chronic hepatitis","volume":"9","author":"Maddrey","year":"1980","journal-title":"Clinical Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003181.pub2-BIB0089|cit89","first-page":"C47","article-title":"Current and future treatment of hepatitis C","volume":"20","author":"Manns","year":"2001","journal-title":"Indian Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD003181.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/hep.510250340","article-title":"Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype","volume":"25","author":"Mihm","year":"1997","journal-title":"Hepatology"},{"issue":"9128","key":"10.1002\/14651858.CD003181.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervetion efficacy reported in meta-analyses","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000369","article-title":"Interferon for acute hepatitis C","author":"Myers","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000370","article-title":"Interferon for interferon naive patients with chronic hepatitis C","author":"Myers","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003181.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/hep.1840120221","article-title":"Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration","volume":"12","author":"Nakagawa","year":"1990","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/archinte.1972.03650040130012","article-title":"Bile acids, liver injury and liver disease","volume":"130","author":"Palmer","year":"1972","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003181.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholiic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD003181.pub2-BIB0097|cit97","first-page":"I","article-title":"Tauroursodeoxycholic acid for the treatment of chronic hepatitis: a dose-response study (IASL Abstract)","volume":"23","author":"Podda","year":"1996","journal-title":"Hepatology"},{"issue":"9055","key":"10.1002\/14651858.CD003181.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1053\/jhep.2002.32533","article-title":"Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes","volume":"35","author":"Qiao","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-2008-1040523","article-title":"Side effects of alpha interferon","volume":"9","author":"Renault","year":"1989","journal-title":"Seminar in Liver Disease"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0101|cit101","first-page":"417","article-title":"Hepatitis delta virus disease","volume":"8","author":"Rizzetto","year":"1986","journal-title":"Progress in Liver Disease"},{"issue":"3","key":"10.1002\/14651858.CD003181.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2893.2000.00219.x","article-title":"Apoptotic cell death does not parallel other indicators of liver damage in chronic hepatitis C patients","volume":"7","author":"Rodrigues","year":"2000","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"10.1002\/14651858.CD003181.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003181.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/hep.1840360702","article-title":"National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD003181.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.1840040416","article-title":"Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties","volume":"4","author":"Sholmerich","year":"1984","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0106|cit106","first-page":"790","article-title":"Hepatitis A and Hepatitis E","volume-title":"Infectious Disease","author":"Stapleton","year":"1994"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0107|cit107","article-title":"Trials sequential analyses of six Cochrane Neonatal Group meta-analyses","volume":"(in press)","author":"Wetterslev","year":"2007","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0108|cit108","unstructured":"WHO Hepatitis B Fact Sheet WHO\/204, www.who.int\/inf-fs\/en\/fact204.html October 2000"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0109|cit109","unstructured":"WHO Hepatitis C Fact Sheet WHO\/164, www.who.int\/inf-fs\/en\/fact164.html October 2000"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0110|cit110","first-page":"827","article-title":"The viruses of hepatitis","volume-title":"Oxford Textbook of Clinical Hepatology","volume":"1","author":"Wolfram","year":"1999"},{"key":"10.1002\/14651858.CD003181.pub2-BIB0111|cit111","volume-title":"Viral Hepatitis","author":"Zuckermann","year":"1993"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003181.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:47:57Z","timestamp":1756712877000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003181.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Hepato-Biliary Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2007,10,17]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003181.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,17]]}}}